HTBX Heat Biologics Inc.

+0.01  (+1%)
Previous Close 1.28
Open 1.27
Price To Book 1.7
Market Cap 41869716
Shares 32,457,144
Volume 213,828
Short Ratio
Av. Daily Volume 270,435

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 4Q 2018.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
Bladder cancer
Phase 1b data released December 6, 2016.
Non-small cell lung cancer (NSCLC)

Latest News

  1. HTBX: Plenty of Catalysts in 2019
  2. Durham company rakes in another $13.8M through public offering
  3. Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering
  4. Heat Biologics to Participate in Panel Presentation at the Goldman Sachs Asia Pacific Healthcare Forum
  5. Detailed Research: Economic Perspectives on Whirlpool, GrafTech International, Thermon Group, White Mountains Insurance Group, Air Industries Group, and Heat Biologics — What Drives Growth in Today's Competitive Landscape
  6. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  7. Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Historical Volatility?
  8. The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO
  9. Heat Biologics, Inc. Prices $12,000,000 Public Offering
  10. Heat Biologics, Inc. Announces Proposed Public Offering
  11. Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update
  12. Heat Biologics to Present at Precision: Lung Cancer World R&D Summit
  13. Heat Biologics CEO to Participate in Panel Presentation at The Cellular ''Living Drug'' Revolution Summit in New York City
  14. Heat Biologics to Present at the 2018 BIO Investor Forum
  15. Heat Biologics’ Pelican Subsidiary Provides Update on its Novel PTX-35 T-Cell Costimulator
  16. What does Heat Biologics Inc’s (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future?
  17. HTBX: Multiple Milestones on the Horizon
  18. Heat Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City
  19. Heat Biologics Stock Is a Worthwhile, Speculative Bet
  20. Heat Biologics Reports Second Quarter 2018 Results and Provides Corporate Update